Outcomes of Pregnancies Fathered by Inflammatory Bowel Disease Patients Exposed to Thiopurines

[1]  J. Martin,et al.  Births: final data for 2005. , 2007, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[2]  M. Owen,et al.  Agreement between maternal report and antenatal records for a range of pre and peri-natal factors: the influence of maternal and child characteristics. , 2007, Early human development.

[3]  H. Sørensen,et al.  Therapeutic Drug Use in Women With Crohn's Disease and Birth Outcomes: A Danish Nationwide Cohort Study , 2007, The American Journal of Gastroenterology.

[4]  S. Jeng,et al.  Severe obstetric complications and birth characteristics in preterm or term delivery were accurately recalled by mothers. , 2006, Journal of clinical epidemiology.

[5]  A. Forbes,et al.  European evidence based consensus on the diagnosis and management of Crohn’s disease: current management , 2006, Gut.

[6]  H. Tilg,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. , 2010, Journal of Crohn's & colitis.

[7]  S. Badaan,et al.  Effects of 6-mercaptopurine treatment on sperm production and reproductive performance: A study in male mice , 2005, Scandinavian journal of gastroenterology.

[8]  M. Tsuang,et al.  The retrospective measurement of prenatal and perinatal events: accuracy of maternal recall , 2004, Schizophrenia Research.

[9]  C. Bodian,et al.  The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients , 2004, American Journal of Gastroenterology.

[10]  B. Nørgård,et al.  The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception , 2004, Alimentary pharmacology & therapeutics.

[11]  B. Nørgård,et al.  Azathioprine, mercaptopurine and birth outcome: a population‐based cohort study , 2003, Alimentary pharmacology & therapeutics.

[12]  E. Alstead.  Inflammatory bowel disease in pregnancy , 2002, Postgraduate medical journal.

[13]  C. Mittermaier,et al.  Azathioprine treatment and male fertility in inflammatory bowel disease. , 2001, Gastroenterology.

[14]  Allan Donner,et al.  Design and Analysis of Cluster Randomization Trials in Health Research , 2001 .

[15]  R. Modigliani,et al.  [Pregnancy outcome in inflammatory bowel diseases]. , 1999, Gastroentérologie Clinique et Biologique.

[16]  B. Korelitz,et al.  Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease , 1998, American Journal of Gastroenterology.

[17]  A. Templeton.  Infertility-epidemiology, aetiology and effective management. , 1995, Health bulletin.

[18]  G. Fick,et al.  Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.

[19]  R. T. Lie,et al.  A Population-Based Study of the Risk of Recurrence of Birth Defects , 1994 .

[20]  J. Lennard-jones,et al.  Safety of azathioprine in pregnancy in inflammatory bowel disease. , 1990, Gastroenterology.

[21]  Clarice R. Weinberg,et al.  Incidence of early loss of pregnancy. , 1988, The New England journal of medicine.

[22]  S. Riley,et al.  Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. , 1987, Gut.

[23]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[24]  A. Traub,et al.  MALE INFERTILITY DUE TO SULPHASALAZINE , 1979, The Lancet.

[25]  A. Levi,et al.  MALE INFERTILITY DUE TO SULPHASALAZINE , 1979, The Lancet.

[26]  T. Starzl,et al.  Parenthood in renal homograft recipients. , 1971, JAMA.

[27]  M. Golby.  FERTILITY AFTER RENAL TRANSPLANTATION , 1970, Transplantation.

[28]  Vicente Fúster Siebert,et al.  La Evolución del Peso al Nacer en España (1981-2002) y su relación con las Características de la Reproducción , 2005 .

[29]  M. Hod,et al.  Is immunosuppression therapy in renal allograft recipients teratogenic? A single‐center experience , 2003, American journal of medical genetics. Part A.

[30]  C. Bodian,et al.  The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. , 2003, Gastroenterology.

[31]  Y. Hiki,et al.  Enzymatically deglycosylated human IgA1 molecules accumulate and induce inflammatory cell reaction in rat glomeruli. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  F. Berthoux.  SECTION IV: Long-term management of the transplant recipient , 2002 .

[33]  Z. Ackerman,et al.  WAGR syndrome in a baby—the result of 6-MP treatment in a father affected by Crohn's disease? , 2001, American Journal of Gastroenterology.

[34]  R. Gokal,et al.  Outcome of pregnancy following renal transplantation. , 2000, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[35]  G. Fick,et al.  Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. , 1995, Annals of internal medicine.

[36]  R. T. Lie,et al.  A population-based study of the risk of recurrence of birth defects. , 1994, The New England journal of medicine.